Peptide Industry News: Late May 2026 Roundup

The FDA has proposed permanently excluding semaglutide, tirzepatide, and liraglutide from the 503B bulks list, signaling an end to large-scale GLP-1 compounding regardless of future shortages. Meanwhile, the oral obesity pill market is heating up with Eli Lilly's Foundayo launch directly competing with Novo Nordisk's Wegovy pill. Here's what researchers and patients need to know.

FDA Proposes Permanent 503B Exclusion for GLP-1 Drugs

On April 30, 2026, the FDA published a proposal to exclude semaglutide, tirzepatide, and liraglutide from the Section 503B Bulk Drug Substances List. If finalized, this rule would prohibit 503B outsourcing facilities from compounding these drugs from bulk substances under any circumstances.

"When FDA-approved drugs are available, outsourcing facilities cannot lawfully compound using bulk drug substances unless there is a clear clinical need," said FDA Commissioner Marty Makary. The FDA reviewed nominations and found insufficient evidence of clinical need.

What This Means

The proposal is significant because it would apply regardless of future market conditions. Unlike the temporary shortage-related compounding that occurred from 2022-2025, this rule would permanently close the 503B pathway for these three GLP-1 medications.

Key dates:

• Comment period ends June 29, 2026
• Applies only to 503B outsourcing facilities
• Does not directly affect 503A pharmacies (patient-specific prescriptions)
• Liraglutide remains on shortage list, so compounding continues for now

Safety Concerns Driving the Decision

The FDA cited over 775 adverse event reports linked to compounded GLP-1s as of early 2025:

• 455+ reports for compounded semaglutide
• 320+ reports for compounded tirzepatide
• Many involved dosing errors from multi-dose vials requiring hospitalization

At one point in 2024, compounded versions accounted for roughly 30% of total US GLP-1 supply.

Oral Obesity Pill Competition Heats Up

Foundayo Launches at $149/Month

The FDA approved Eli Lilly's Foundayo (orforglipron) in April 2026, making it the first new molecular entity approved under the National Priority Voucher Program. The approval was notable for being the fastest NME approval since 2002.

Key differentiators for Foundayo:

• Once-daily oral pill (small molecule, not a peptide)
• No food or water restrictions (can take any time of day)
• $149/month self-pay via LillyDirect
• $25/month with commercial insurance
• 12.4% average weight loss in adherent patients

Foundayo is being studied for additional indications including type 2 diabetes, obstructive sleep apnea, osteoarthritis knee pain, and peripheral artery disease.

Wegovy Pill vs Foundayo

The oral GLP-1 market now has direct competition:

When the Wegovy pill launched in January, telehealth provider LifeMD reported its business doubled almost overnight, going from 300-400 new patients daily to 600-1,000.

ATTAIN-MAINTAIN: Orforglipron for Weight Maintenance

At the European Congress on Obesity in Istanbul on May 13, 2026, Eli Lilly presented results from the ATTAIN-MAINTAIN trial, published simultaneously in Nature Medicine.

The trial addressed a practical question: can patients switching from injectable GLP-1s to an oral option maintain their weight loss?

Results by Prior Treatment

Patients previously on tirzepatide:

• Orforglipron maintained 78.0% of weight loss vs 49.8% with placebo
• Maintained approximately 20kg of original weight loss
• Regained only about 5kg during the 52-week trial

Patients previously on semaglutide:

• Orforglipron maintained 82.4% of weight loss vs 38.3% with placebo
• Maintained approximately 18kg of original weight loss
• Regained only about 1kg during the trial

The results suggest orforglipron could serve as an "oral maintenance" option for patients who want to stop injections after achieving their weight loss goals.

CagriSema Under FDA Review

Novo Nordisk's CagriSema (cagrilintide + semaglutide combination) is currently under FDA review following the December 2025 submission.

REDEFINE Trial Results

Published data from the Phase III REDEFINE program showed:

REDEFINE 1 (obesity without diabetes):

• 22.7% mean weight loss at 68 weeks
• 60% of patients achieved 20%+ weight loss
• 23% achieved 30%+ weight loss
• 88% of prediabetic patients returned to normoglycemia

REDEFINE 2 (obesity with type 2 diabetes):

• 73.5% achieved HbA1c below 6.5% vs 15.9% with placebo
• Significant improvements in glycemic control

Novo Nordisk plans to initiate a high-dose CagriSema trial (2.4mg/7.2mg) in the second half of 2026.

Novo Nordisk Announces Major Price Cuts

On February 24, 2026, Novo Nordisk announced it will reduce list prices effective January 1, 2027:

• Wegovy (injection and tablets): ~50% reduction to $675
• Ozempic: ~35% reduction to $675
• Rybelsus: Being phased out and unified under Ozempic brand

The price cuts come as Eli Lilly holds a 60.1% share of the US obesity and diabetes drug market compared to Novo's 39.4% in Q1 2026. While Lilly expects 28% sales growth this year, Novo projects a 4-12% decline in profits and sales due to lower US prices and generic competition in international markets.

Pipeline Watch: What's Coming Next

Amycretin (Novo Nordisk)

The GLP-1/amylin dual agonist entered Phase 3 trials in Q1 2026 for both obesity and type 2 diabetes. Phase 2 data showed up to 14.5% weight loss with weekly injections and 10.1% with the oral version over 36 weeks. If successful, approval is anticipated around Q4 2030.

Survodutide (Boehringer Ingelheim)

The GLP-1/glucagon dual agonist targeting liver fat showed 83% MASH histological improvement in Phase 2. Phase 3 SYNCHRONIZE results are expected late 2026.

Retatrutide (Eli Lilly)

Following the TRIUMPH-1 results showing 28.3% weight loss, Eli Lilly continues seven additional Phase 3 trials through 2026. The triple GLP-1/GIP/glucagon agonist remains on track for FDA submission.

Market Context

The global peptide therapeutics market stands at approximately $164 billion in 2026 and is projected to reach $295 billion by 2033 (8.7% CAGR).

Key industry shifts:

• Peptide Sciences, the largest gray-market research peptide vendor, voluntarily closed on March 6, 2026
• Capital is shifting toward companies with regulatory engagement and scalable production
• Legal and compliance risk is reshaping business planning across the industry

What to Watch

June 29, 2026: Deadline for public comments on FDA's 503B GLP-1 exclusion proposal

July 23-24, 2026: FDA PCAC meeting on BPC-157, TB-500, MOTS-c, KPV, Epitalon, Semax, and Emideltide

Late 2026: Survodutide SYNCHRONIZE Phase 3 results expected

2026: FDA decision on CagriSema expected

---

This content is for informational purposes only and does not constitute medical advice. Consult a healthcare provider before using any peptides or medications.

Frequently Asked Questions

Will compounded semaglutide and tirzepatide become illegal?

The FDA's proposal only affects 503B outsourcing facilities. If finalized, these facilities could no longer compound semaglutide, tirzepatide, or liraglutide from bulk substances. 503A pharmacies (traditional compounding pharmacies filling patient-specific prescriptions) operate under different rules and would not be directly affected by this proposal. However, the 503A pathway is more limited in scale.

What's the difference between Foundayo and the Wegovy pill?

Foundayo (orforglipron) is a small-molecule GLP-1 agonist that can be taken any time of day without food or water restrictions. The Wegovy pill (oral semaglutide) must be taken 30 minutes before food with only a small sip of water. Both are priced at $149/month for self-pay. The Wegovy pill showed higher weight loss (16.6% vs 12.4%) in clinical trials.

Can I switch from injectable Wegovy to oral orforglipron?

The ATTAIN-MAINTAIN trial specifically studied this scenario. Patients switching from injectable semaglutide to oral orforglipron maintained 82.4% of their weight loss over 52 weeks. Discuss any medication changes with your prescribing physician.

When will CagriSema be available?

Novo Nordisk submitted CagriSema for FDA approval in December 2025. FDA review typically takes 10-12 months, so a decision is expected sometime in 2026. If approved, commercial availability would follow.

Sources

• FDA Proposes to Exclude Semaglutide, Tirzepatide, and Liraglutide on 503B Bulks List
• Orforglipron for maintenance of body weight reduction - Nature Medicine
• FDA approves Lilly's Foundayo - Eli Lilly Investor Relations
• Novo Nordisk files for FDA approval of CagriSema
• Novo Nordisk price reduction announcement
• FDA Moves to Permanently Close the Door on Compounded GLP-1s - Pharmacy Times
• ECO 2026: ATTAIN-MAINTAIN trial - Pharmaceutical Technology